<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04465370</url>
  </required_header>
  <id_info>
    <org_study_id>2019-08</org_study_id>
    <nct_id>NCT04465370</nct_id>
  </id_info>
  <brief_title>Pediatric Cardiac Output Monitoring Observational Study</brief_title>
  <acronym>POGO</acronym>
  <official_title>A Prospective, Single-Arm, Nonrandomized, Observational Study of Cardiac Output Monitoring in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess Cardiac Output Monitoring in pediatric subjects by comparing FloTrac and ClearSight&#xD;
      system to intermittent thermodilution Swan-Ganz, in order to expand the indications of&#xD;
      FloTrac, ClearSight and Swan-Ganz thermodilution pulmonary artery catheter to the pediatric&#xD;
      population 12 to 18 years of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstration of monitoring cardiac output with Swan-Ganz, FloTrac, and ClearSight system</measure>
    <time_frame>Duration of the procedure through 30 days after procedure, plus or minus 14 days</time_frame>
    <description>Demonstrate that monitoring of cardiac output with Swan-Ganz, FloTrac, and ClearSight system is comparable as determined by the Bland-Altman method of bias.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate that monitoring of cardiac output with Swan-Ganz, FloTrac, and ClearSight system is comparable as determined by the Critchley and Critchley method of percent error calculation.</measure>
    <time_frame>Duration of the procedure through 30 days after procedure, plus or minus 14 days</time_frame>
    <description>Demonstrate that monitoring of cardiac output with Swan-Ganz, FloTrac, and ClearSight system is comparable as determined by the Critchley and Critchley method of percent error calculation.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Pediatric ALL</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight</intervention_name>
    <description>A Swan-Ganz catheter, FloTrac transducer, ClearSight finger cuff and ForeSight Elite sensors will be placed prior to the start of the catheterization procedure. Intermittent cardiac output and other hemodynamic parameters will be collected throughout the duration of the procedure and analyzed according to the Statistical Analysis Plan.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males and Females, 12 to 18 years of age at the time of screening. Who presenting to&#xD;
        Cardiac Catheterization Lab for right heart catheterizations.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are 12 to 18 years of age&#xD;
&#xD;
          -  Subjects who have signed the Informed Consent Form&#xD;
&#xD;
          -  Subjects who are projected to receive Swan-Ganz catheter as part of procedure/standard&#xD;
             of care with intermittent cardiac output measures&#xD;
&#xD;
          -  For those Subjects who have had a cardiac transplant,Subjects who are at least 2 weeks&#xD;
             post cardiac transplantation&#xD;
&#xD;
          -  Subjects with planned pressure monitoring with an arterial line&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with contraindications for Pulmonary Artery Catheters Placement and&#xD;
             monitoring (recurrent sepsis, or with hypercoagulopathy);&#xD;
&#xD;
          -  Subjects with contraindications for Arterial Line Placement;&#xD;
&#xD;
          -  Subjects with an extreme contraction of the smooth muscle in the arteries and&#xD;
             arterioles in the lower arm and hand (i.e., Raynaud's Disease).&#xD;
&#xD;
          -  Subjects with a physical site area too limited for proper Sensor placement&#xD;
&#xD;
          -  Subjects with finger size less than the smallest finger cuff size&#xD;
&#xD;
          -  Documented ≥ moderate pulmonary hypertension (PAPm &gt; 25mmHg, PVRI &gt; 3.0 WUxm2)&#xD;
&#xD;
          -  Presence of intracardiac shunting (i.e., ASD, VSD)&#xD;
&#xD;
          -  Aorto-pulmonary collaterals&#xD;
&#xD;
          -  ≥ Moderate tricuspid regurgitation, per echocardiogram criteria&#xD;
&#xD;
          -  &gt; Moderate Aortic or pulmonary regurgitation, per echocardiogram criteria&#xD;
&#xD;
          -  Persistent cardiac arrythmias during the cardiac catheterization period (&gt; 3min)&#xD;
&#xD;
          -  Vascular abnormalities of the arterial system (i.e., connective tissue disorders,&#xD;
             mid-aortic syndrome)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathy Akagha</last_name>
    <phone>(949) 250-7169</phone>
    <email>Kathy_Akagha@edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UF Health Shands Children's Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalia Lopez-Colon</last_name>
      <phone>352-273-7770</phone>
      <email>dalylc@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Reilly</last_name>
      <email>REILLYS1@chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Tume, MD</last_name>
      <email>sctume@texaschildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodynamic Monitoring</keyword>
  <keyword>Cardiac Output</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

